The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 11-12, 2015, Pages 1315-1326

  Scott, D R ^a,b   Munson, K B ^a,b   Marcus, E A ^a,b   Lambrecht, N W G ^c   Sachs, G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; MALE; MOLECULAR MODEL; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; HALF LIFE TIME; METABOLISM; RABBIT; STOMACH; STOMACH ACID; STOMACH MUCOSA; STOMACH PARIETAL CELL;

ANIMALS; GASTRIC ACID; GASTRIC MUCOSA; H(+)-K(+)-EXCHANGING ATPASE; HALF-LIFE; MALE; PARIETAL CELLS, GASTRIC; PROTON PUMP INHIBITORS; PYRROLES; RABBITS; STOMACH; SULFONAMIDES;

EID: 84946483436     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13414     Document Type: Article

References (40)

1. (+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995; 109: 1134-41.
2. + ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
3. Viani F, Verdu EF, Idstrom JP, et al,. Effect of omeprazole on regional and temporal variations in intragastric acidity. Digestion 2002; 65: 2-10.
4. +)-ATPase and H+ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N, N-diethylamino)octyl-3,4,5-trimethoxybenzoate. Biochim Biophys Acta 1984; 770: 65-72.
5. Ene MD, Khan-Daneshmend T, Roberts CJ,. A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br J Pharmacol 1982; 76: 389-91.
6. +)-ATPase. Prog Clin Biol Res 1988; 273: 255-60.
7. +-competitive photoaffinity inhibitor. Biochemistry 1988; 27: 3932-8.
8. Wallmark B, Briving C, Fryklund J, et al,. Inhibition of gastric H+, K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 1987; 262: 2077-84.
9. Beil W, Hackbarth I, Sewing KF,. Mechanism of gastric antisecretory effect of SCH 28080. Br J Pharmacol 1986; 88: 19-23.
10. + access to the ion binding domain. Biochemistry 2002; 41: 12755-62.
11. Kim HK, Park SH, Cheung DY, et al,. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol 2010; 25: 1618-25.
12. Dent J, Kahrilas PJ, Hatlebakk J, et al,. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.
13. +-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2006; 291: G838-43.
14. Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
15. Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
16. Shin JM, Munson K, Vagin O, Sachs G,. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch 2009; 457: 609-22.
17. Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
18. Scott DR, Helander HF, Hersey SJ, Sachs G,. The site of acid secretion in the mammalian parietal cell. Biochim Biophys Acta 1993; 1146: 73-80.
19. Berglindh T, Obrink KJ,. A method for preparing isolated glands from the rabbit gastric mucosa. Acta Physiol Scand 1976; 96: 150-9.
20. Munson K, Garcia R, Sachs G,. Inhibitor and ion binding sites on the gastric H, K-ATPase. Biochemistry 2005; 44: 5267-84.
21. Trott O, Olson AJ,. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31: 455-61.
22. (+)-ATPase. J Exp Biol 2000; 203: 161-70.
23. +-ATPase reveals an important contribution of the A-M2 linker for the luminal gating. J Biol Chem 2014; 289: 30590-601.
24. (+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme. J Med Chem 1991; 34: 533-41.
25. (+)-competitive inhibitors in the gastric proton pump. J Biol Chem 2004; 279: 13968-75.
26. Simon WA, Herrmann M, Klein T, et al,. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007; 321: 866-74.
27. Munson K, Law RJ, Sachs G,. Analysis of the gastric H, K ATPase for ion pathways and inhibitor binding sites. Biochemistry 2007; 46: 5398-417.
28. Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G,. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci 2008; 65: 264-81.
29. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T,. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
30. Mejia A, Kraft WK,. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol 2009; 2: 295-314.
31. Sachs G, Shin JM, Hunt R,. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010; 12: 437-47.
32. Arikawa Y, Nishida H, Kurasawa O, et al,. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012; 55: 4446-56.
33. Nishida H, Hasuoka A, Arikawa Y, et al,. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg Med Chem 2012; 20: 3925-38.
34. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB,. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
35. Luo HJ, Deng WQ, Zou K,. Protonated form: the potent form of potassium-competitive acid blockers. PLoS ONE 2014; 9: e97688.
36. Garnock-Jones KP,. Vonoprazan: first global approval. Drugs 2015; 75: 439-43.
37. Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94.
38. Sakurai Y, Mori Y, Okamoto H, et al,. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42: 719-30.
39. Ashida K, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42: 685-95.
40. Yuan Y, Hunt RH,. Intragastric pH holding time of pH<4 predicts low erosive esophagitis (EE) healing rate. Gastroenterology 2010; 138 (5 Suppl. 1): S651.